Product Description: Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD)[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Yu-Ling Wei, et al. Strategies to evaluate potential effector function of glycan variants: a case study of ordesekimab (AMG 714 or PRV-015). J Immunotoxicol. 2022 Dec;19(1):109-116.